Ukr.Biochem.J. 2018; Volume 90, Issue 5, Sep-Oct, pp. 91-97

doi: https://doi.org/10.15407/ubj90.05.091

The indices of nitrogen (II) oxide system in experimental hepatopulmonary syndrome

25.09.2018   Uncategorized   No comments

I. Ya. Krynytska, M. I. Marushchak

I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine;
e-mail: marushchak@tdmu.edu.ua

Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver disease characterized by arterial hypoxemia. Altered nitrogen (II) oxide (NO) production has also been implicated in the pathogenesis of the HPS. The present study was designed to evaluate the indices of NO system in the blood serum and lung tissue of animals with different models of hepatopulmonary syndrome. The total NOS activity was performed by monitoring the rate of conversion of L-arginine into citrulline. The total contents of NO metabolites was assessed by evaluation of their amount, which included nitrite ions that were previously presented in the sample (NO2–) and also nitrate ions reducted to nitrites (NO3–). We found a significant increase in total NOS activity in the lung tissue of Rats of both experimental groups  as compared to control animals, but it was greater in the rats on the 28th day after the common bile duct ligation. The total concentration of NO2– + NO3– in the lung tissue of the rats in the experimental group N 1 also significantly increased (5.8 times) and in the rats of the experimental group with carbon – 4.5 times (P < 0.001) vs the control group. Thus, in rats with different models of hepatopulmonary syndrome the activation of nitroxydergic process by a significant increase in nitrogen (II) oxide metabolites contents and total NO synthases activity has been established. Herewith a more pronounced intensification of nitroxydergic processes was observed in rats on the 28th day after the common bile duct ligation.

Keywords: , , ,

References:

  1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014 Sep 18;12:145. PubMed, PubMedCentral, CrossRef
  2. Abrahamovych O, Abrahamovych M, Tolopko S, Ferko M. Character and frequency of the variations of co- and polymorbid syntropic extrahepatic lesions and their dependence on the hepatopulmonary syndrome severity degree in cirrhotic patients. Georgian Med News. 2016; 11(260): 34–41. PubMed
  3. Amin Z, Amin HZ, Tedyanto NM. Hepatopulmonary Syndrome: A Brief Review. Rom J Intern Med. 2016 Apr-Jun;54(2):93-7. PubMed, CrossRef
  4. Cosarderelioglu C, Cosar AM, Gurakar M, Dagher NN, Gurakar A. Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature. J Clin Transl Hepatol. 2016 Mar 28;4(1):47-53.  PubMed, PubMedCentral, CrossRef
  5. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004 Nov;24(5):861-80. PubMed, CrossRef
  6. Krynytska I, Marushchak M, Mikolenko A, Bob A, Smachylo I, Radetska L, Sopel O. Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT). Bosn J Basic Med Sci. 2017 Nov 20;17(4):276-285. PubMed, PubMedCentral, CrossRef
  7. Zhang J, Fallon MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):539-49. PubMed, CrossRef
  8. Ilchenko LYu, Fedorov IG, Karabinenko AA, Oskanova RS, Storozhakov GI. Hepatopulmonary syndrome: state of problem. Sovr Tekhnol Med. 2009;(1): 84–8.
  9. Krynytska IYa, Marushchak MI, Klishch IM, Birchenko IV. Molecular mechanisms of hepatopulmonary syndrome. Fiziol Zh. 2017; 63(3): 90-102. CrossRef
  10. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. Council of Europe Strasbourg 1986; 123: 52.
  11. Fallon MB, Abrams GA, McGrath JW, Hou Z, Luo B. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol. 1997 Apr;272(4 Pt 1):G779-84. PubMed, CrossRef
  12. Zhang HY, Han DW, Zhao ZF, Liu MS, Wu YJ, Chen XM, Ji C. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J Gastroenterol. 2007 Jul 7;13(25):3500-7. PubMed, PubMedCentral, CrossRef
  13. Fafula RV, Iefremova UP, Onufrovych OK, Maksymyuk HV, Besedina AS, Nakonechnyi IA, Vorobets DZ, Vorobets ZD. Alterations in arginase-no-synthase system of spermatozoa in human subjects with different fertility potential. J Med Biochem. 2018; 37(2): 134–40. CrossRef
  14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265-75. PubMed
  15. Kozar VV, Kudrya MY, Ustenko NV, Nikishina LE, Kravchenko SV. Determination of the concentration of metabolites of nitric oxide in serum. Lab Diagnost. 2010; (3): 14–16. (In Ukrainian).
  16. Dinh-Xuan AT, Naeije R. The hepatopulmonary syndrome: NO way out? Eur Respir J. 2004 May;23(5):661-2. PubMed, CrossRef
  17. Zhang HY, Han DW, Su AR, Zhang LT, Zhao ZF, Ji JQ, Li BH, Ji C. Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. World J Gastroenterol. 2007 Dec 21;13(47):6385-95.  PubMed, PubMedCentral, CrossRef
  18. Bosco AD, Schedler FB, Colares JR, Dias AS, Marroni NP. Hepatopulmonary syndrome: oxidative stress and physical exercise. EMJ. 2017;2(4):69-75.
  19. Gill SS, Suri SS, Janardhan KS, Caldwell S, Duke T, Singh B. Role of pulmonary intravascular macrophages in endotoxin-induced lung inflammation and mortality in a rat model. Respir Res. 2008 Oct 24;9(1):69. PubMed, PubMedCentral, CrossRef
  20. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S138-42. PubMed, CrossRef
  21. Hamamoto J, Toba S, Hirosako S, Nakamura K, Fujii K, Kohrogi H. A case of hepatopulmonary syndrome with elevated exhaled nitric oxide. Nihon Kokyuki Gakkai Zasshi. 2010 May;48(5):379-84. PubMed
  22. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, Ottobrelli A, Cerutti E, Polizzi S, Bucca C. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med. 1998 Sep 1;129(5):375-8. PubMed, CrossRef
  23. Degano B, Mittaine M, Hervé P, Rami J, Kamar N, Suc B, Rivière D, Rostaing L. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. Eur Respir J. 2009 Jul;34(1):138-44. PubMed, CrossRef
  24. Delclaux C, Mahut B, Zerah-Lancner F, Delacourt C, Laoud S, Cherqui D, Duvoux C, Mallat A, Harf A. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med. 2002 Feb 1;165(3):332-7. PubMed, CrossRef
  25. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, Dinh-Xuan AT, Simonneau G, Hervé P. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001 Sep 1;164(5):879-85. PubMed, CrossRef
  26. 26. Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, Grizzle WE, Fallon MB. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology. 2003 Nov;125(5):1441-51. PubMed, CrossRef
  27. Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet. 2003 Jul 5;362(9377):43-4. PubMed, CrossRef
  28. Aksu B, Umit H, Kanter M, Guzel A, Aktas C, Civelek S, Uzun H. Effects of methylene blue in reducing cholestatic oxidative stress and hepatic damage after bile-duct ligation in rats. Acta Histochem. 2010 May;112(3):259-69. PubMed, CrossRef
  29. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000 Nov 7;133(9):701-6. PubMed, CrossRef
  30. Gómez FP, Barberà JA, Roca J, Burgos F, Gistau C, Rodríguez-Roisin R. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology. 2006 May;43(5):1084-91. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.